Drugmaker Merck has created Molnupiravir, a new antiviral pill created to fight against the COVID-19 virus. This is a new approach considering all virus-fighting has come from vaccines so far.
At the time of reporting this news, this COVID-19 pill has not been cleared by the Food and Drug Administration.
This pill won’t eliminate your chances of getting the virus entirely, just like the vaccine doesn’t. It was, however, made to reduce the symptoms that those suffering from COVID-19 feel.
Molnupiravir, the COVID-19 pill, is recommended for “high-risk adults,” according to Yale Medicine. Yale Medicine has also stated that only unvaccinated people took part in the pill’s trial.
“In the clinical trial, molnupiravir was mostly given to people who were over 60 or those who were young but had other conditions that put them at high risk of bad outcomes from COVID-19, such as diabetes, heart disease, or obesity,” said Yale Medicine.
There is currently a contract between the U.S. government and this drugmaker that states the drugmaker will supply the U.S. government with 1.7 million courses at $700 per course according to Reuters. “Merck expects to produce 10 million courses of the treatment by the end of 2021,” reported Reuters.
Though the COVID-19 pill is currently being offered to unvaccinated people, this could change in the future. Would you be willing to take this new COVID-19 antiviral pill? Use an emoji below to let us know. In the meantime, don’t forget to wash your hands, mask-up, and get vaxed if you haven’t already.
By Cierra Lemott, Sophomore, Columbia College Chicago
Snapchat & Instagram: @cece.kodak